HESKA RESTR. NEW DL-,001 Logo
US42805E3062
A1H5J3
HSKA

HESKA RESTR. NEW DL-,001

Forecast

The analysts' average price target is €145.36 (+30.95%). The median is €145.36 (+30.95%).

Buy
  8
Hold
  8
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2012, HESKA RESTR. NEW DL-,001 has already paid €0.24 in dividends. The last payout was in October 2012.

Financials

In the last year, HESKA RESTR. NEW DL-,001 had revenue of €239.87m and net profit of -€17.18m

(EUR) 2022
YoY
Revenue 239.87m 7.50%
Gross profit 103.64m 11.39%
Net profit -17.18m 14,896.48%
EBITDA -18.92m 250.32%

Fundamentals

Metric Value
Market capitalization
€1.19bn
Number of shares
10.91m
52-week high/low
€109.39 - €52.70
Dividends No
Beta
1.60
P/E ratio
-67.41
PEG ratio
1.58
P/B ratio
2.94
P/S ratio
5.09

Company profile

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

Name
HESKA RESTR. NEW DL-,001
CEO
Kevin S. Wilson
Headquarters Loveland, co
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
01/07/1997
Employees 808

Ticker symbols

Exchange Symbol
NASDAQ
HSKA
🍪

Parqet  uses cookies. Learn more